Augmentin pills 875mg+125mg, 14pcs

Composition

Active ingredients:

amoxicillin (in the form of trihydrate) – 875 mg;

clavulanic acid (in the form of potassium salt) – 125 mg.

Auxiliary substances:

magnesium stearate – 14.5 mg,

sodium carboxymethyl starch-29 mg,

colloidal silicon dioxide-10 mg,

microcrystalline cellulose-396.5 mg.

Composition of the film shell:

titanium dioxide-13.76 mg,

hypromellose (5 cps) – 10.56 mg,

hypromellose (15 cps) – 3.52 mg,

macrogol 4000-2.08 mg,

macrogol 6000-2.08 mg,

dimethicone-0.013 mg

Pharmacological action

Augmentin – broad-spectrum antibacterial, bactericidal.

Pharmacodynamics

Amoxicillin is a semi-synthetic broad-spectrum antibiotic with activity against many gram-positive and gram-negative microorganisms. At the same time, amoxicillin is susceptible to destruction by beta-lactamases, and therefore the spectrum of activity of amoxicillin does not extend to microorganisms that produce this enzyme.

Clavulanic acid — a beta-lactamase inhibitor structurally related to penicillins, has the ability to inactivate a wide range of beta-lactamases found in penicillin-and cephalosporin-resistant microorganisms.

Clavulanic acid has sufficient efficacy against plasmid beta-lactamases, which are most often responsible for bacterial resistance, and is less effective against chromosomal beta-lactamases of type 1, which are not inhibited by clavulanic acid.

The presence of clavulanic acid in Augmentin® protects amoxicillin from destruction by beta — lactamase enzymes, which allows you to expand the antibacterial spectrum of amoxicillin.

The activity of the combination of amoxicillin with clavulanic acid in vitro is shown below.

Bacteria usually sensitive to the combination of amoxicillin and clavulanic acid

Gram-positive aerobes:  Bacillus anthracis, Enterococcus faecalis, Listeria monocytogenes, Nocardia asteroides, Streptococcus spp., including Streptococcus pyogenes1,2, Streptococcus agalactiae1,2 (other beta-hemolytic streptococci)1,2, Staphylococcus aureus (sensitive to methicillin)1, Staphylococcus saprophyticus (sensitive to methicillin), coagulase-negative staphylococci (sensitive to methicillin).

Gram-positive anaerobes:  Clostridium spp., Peptococcus niger, Peptostreptococcus spp., including Peptostreptococcus magnus, Peptostreptococcus micros.

Gram-negative aerobes:  Bordetella pertussis, Haemophilus influenzae1, Helicobacter pylori, Moraxella cafarrhalis1, Neisseria gonorrhoeae, Pasteurella multocida, Vibrio cholerae.

Gram-negative anaerobes:  Bacteroides spp., including Bacteroides fragilis, Capnocytophaga spp., Eikenella corrodens, Fusobacterium spp., including Fusobacterium nucleatum, Porphyromonas spp., Prevotella spp.

Other services:  Borrelia burgdorferi, Leptospira icterohaemorrhagiae, Treponema pallidum.

Bacteria that are likely to develop resistance to the combination of amoxicillin and clavulanic acid

Gram-negative aerobes:  Escherichia coli1, Klebsiella spp., including Klebsiella oxytoca, Klebsiella pneumoniae1, Proteus spp., including Proteus mirabilis, Proteus vulgaris, Salmonella spp., Shigella spp.

Gram-positive aerobes:  Corynebacterium spp., Enterococcus faecium, Streptococcus pneumoniae1,2, streptococci of the Viridans group.

Bacteria that are naturally resistant to the combination of amoxicillin and clavulanic acid

Gram-negative aerobes:  Acinetobacter spp., Citrobacter freundii, Enterobacter spp., Hafnia alvei, Legionella pneumophila, Morganella morganii, Providencia spp., Pseudomonas spp., Serratia spp., Stenotrophomonas maltophilia, Yersinia enterocolitica.

Other services:  Chlamydia spp., including Chlamydia pneumoniae, Chlamydia psittaci, Coxiella burnetii, Mycoplasma spp.

1 For these bacteria, the clinical efficacy of the combination of amoxicillin with clavulanic acid has been demonstrated in clinical studies.

2 Strains of these bacterial species do not produce beta-lactamase. The sensitivity of amoxicillin monotherapy suggests a similar sensitivity to the combination of amoxicillin with clavulanic acid.

Pharmacokinetics

Suction

Both active ingredients of Augmentin® – amoxicillin and clavulanic acid-are rapidly and completely absorbed from the gastrointestinal tract after oral use. Absorption of active ingredients of Augmentin® optimal in the case of taking the drug at the beginning of a meal.

 Below are data on the pharmacokinetic parameters of amoxicillin and clavulanic acid obtained in different studies when healthy volunteers aged 2-12 years on an empty stomach took 40 mg+10 mg/kg/day of Augmentin®, powder for preparing an oral suspension,125 mg+31.25 mg in 5 ml (156.25 mg) in three doses.

Indications

The combination of amoxicillin with clavulanic acid is indicated for the treatment of bacterial infections of the following locations caused by microorganisms sensitive to the combination of amoxicillin with clavulanic acid:

• upper respiratory tract infections (including ENT infections), such as recurrent tonsillitis, sinusitis, otitis media, usually caused by Streptococcus pneumoniae, Haemophilus influenzae1, Moraxella catarrhalis1 and Streptococcus pyogenes; (except Augmentin 250 mg/125 mg tablets);
• lower respiratory tract infections, such as exacerbations of chronic bronchitis, lobar pneumonia and bronchopneumonia, usually caused by Streptococcus pneumoniae, Haemophilus influenzae1 and Moraxella catarrhalis1;
• urinary tract infections, such as cystitis, urethritis, pyelonephritis, female genital infections, usually caused by species of the Enterobacteriaceae1 family (mainly Escherichia coli1), Staphylococcus saprophyticus and species of the genus Enterococcus, as well as gonorrhea caused by Neisseria gonorrhoeae1;
• skin and soft tissue infections usually caused by Staphylococcus aureus1, Streptococcus pyogenes and species of the genus Bacteroides1;
• infections of the bones and joints, such as osteomyelitis, usually caused by Staphylococcus aureus1, if necessary, long-term therapy is possible.
• odontogenic infections, such as periodontitis, odontogenic maxillary sinusitis, severe dental abscess with spreading cellulitis (only for tablets of Augmentin dosage 500 mg/125 mg,875 mg/125 mg);
• other mixed infections (e. g. septic abortion, puerperal sepsis, intra-abdominal sepsis) in the framework of sequential therapy (only for tablets of Augmentin dosage of 250 mg/125 mg,500 mg/125 mg,875 mg/125 mg);

Use during pregnancy and lactation

In studies of reproductive function in animals, oral and parenteral use of Augmentin® did not cause teratogenic effects.

In a single study in women with premature rupture of the fetal membranes, it was found that preventive therapy with the drug may be associated with an increased risk of developing necrotizing enterocolitis in newborns.

As with all medications, Augmentin® is not recommended for use during pregnancy, except in cases where the expected benefit to the mother exceeds the potential risk to the fetus.

Augmentin® can be used during breastfeeding. With the exception of the possibility of developing diarrhea or candidiasis of the oral mucosa associated with the penetration of trace amounts of active substances of this drug into breast milk, no other adverse effects were observed in children who are breastfed.

In case of adverse effects in children who are breastfed, it is necessary to stop breastfeeding.

Contraindications

Hypersensitivity

Side effects

Infectious and parasitic diseases: often-candidiasis of the skin and mucous membranes.

Blood and lymphatic system disorders: rarely-reversible leukopenia (including neutropenia) and reversible thrombocytopenia; very rarely-reversible agranulocytosis and reversible hemolytic anemia, prolongation of prothrombin time and bleeding time, anemia, eosinophilia, thrombocytosis.

From the immune system:  very rarely – angioedema, anaphylactic reactions, a syndrome similar to serum sickness, allergic vasculitis.

Nervous system disorders: infrequently – dizziness, headache; very rarely-reversible hyperactivity, seizures (seizures can occur in patients with impaired renal function, as well as in those who receive high doses of the drug), insomnia, agitation, anxiety, behavior changes.

Gastrointestinal disorders: adults:  very common-diarrhea, often-nausea, vomiting; children-often-diarrhea, nausea, vomiting; whole population: nausea is most often observed when taking high doses of the drug. If after the start of taking the drug there are undesirable reactions from the gastrointestinal tract, they can be eliminated if you take the drug at the beginning of a meal. Infrequently-digestive disorders; very rarely-antibiotic-associated colitis induced by antibiotics (including pseudomembranous colitis and hemorrhagic colitis), black “hairy” tongue, gastritis, stomatitis.In children, when using the suspension, very rarely there was a change in the color of the surface layer of tooth enamel. Oral care helps prevent discoloration of the tooth enamel, as it is enough to brush your teeth.

Liver and biliary tract disorders: infrequently-a moderate increase in the activity of A and / or ALT (observed in patients receiving beta-lactam antibiotics, but its clinical significance is unknown); very rarely – hepatitis and cholestatic jaundice (these phenomena were observed during therapy with other penicillins and cephalosporins), an increase in the concentration of bilirubin and alkaline phosphatase. Adverse events from the liver were observed mainly in men and elderly patients and may be associated with long-term therapy. These adverse events are very rare in children.

These signs and symptoms usually occur during or immediately after the end of therapy, but in some cases they may not appear for several weeks after the end of therapy. Adverse events are usually reversible. Adverse events from the liver can be severe, and in extremely rare cases, fatal outcomes have been reported. In almost all cases, these were people with serious comorbidities or those receiving potentially hepatotoxic drugs at the same time.

Skin and subcutaneous tissue disorders: infrequently-rash, pruritus, urticaria; rarely-erythema multiforme; very rarely-Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous exfoliative dermatitis, acute generalized exanthematous pustulosis.

In case of allergic skin reactions, treatment with Augmentin® should be discontinued.

From the side of the kidneys and urinary tract: very rarely – interstitial nephritis, crystalluria, hematuria.

Interaction

Concomitant use of Augmentin and probenecid is not recommended. Probenecid reduces the tubular secretion of amoxicillin, and therefore the simultaneous use of Augmentin® and probenecid may lead to an increase and persistence in the blood concentration of amoxicillin, but not clavulanic acid.

Concomitant use of allopurinol and amoxicillin may increase the risk of allergic skin reactions. Currently, there is no data in the literature on the simultaneous use of a combination of amoxicillin with clavulanic acid and allopurinol. Penicillins can slow the elimination of methotrexate from the body by inhibiting its tubular secretion, therefore, the simultaneous use of Augmentin® and methotrexate may increase the toxicity of methotrexate.

Like other antibacterial drugs, Augmentin® may affect the intestinal microflora, leading to a decrease in the absorption of estrogens from the gastrointestinal tract and a decrease in the effectiveness of combined oral contraceptives.

The literature describes rare cases of an increase in the international normalized ratio (MHO) in patients with the combined use of acenocoumarol or warfarin and amoxicillin. If it is necessary to co-administer Augmentin® with anticoagulants, prothrombin time or MHO should be carefully monitored when prescribing or discontinuing Augmentin®, and dose adjustment of oral anticoagulants may be required.

How to take, course of use and dosage

The dosage regimen is set individually depending on the age, body weight, kidney function of the patient, as well as the severity of the infection.

For optimal absorption and reduction of possible side effects from the digestive system, Augmentin® is recommended to be taken at the beginning of a meal.

The minimum course of antibacterial therapy is 5 days.

Treatment should not be continued for more than 14 days without reviewing the clinical situation.

If necessary, it is possible to conduct step therapy (at the beginning of therapy, parenteral use of the drug with subsequent transition to oral use).

Adults and children over 12 years of age or weighing 40 kg or more

1 tablet 250 mg / 125 mg 3 times / day (for mild and moderate infections), or 1 tablet 500 mg/125 mg 3 times/day, or 1 tablet 875 mg/125 mg 2 times/day, or 11 ml suspension 400 mg/57 mg/5 ml 2 times/day (equivalent to 1 tablet 875 mg/125 mg).

2 250 mg/125 mg tablets are not equivalent to 1 500 mg/125 mg tablet.

Children from 3 months to 12 years of age with a body weight of less than 40 kg

The drug is prescribed in the form of a suspension for oral use.

The dose is calculated depending on age and body weight, indicated in mg / kg of body weight/day (calculated according to amoxicillin) or in ml of suspension.

The frequency of taking the suspension 125 mg / 31.25 mg in 5 ml is 3 times / day every 8 hours.

The frequency of taking the suspension 200 mg / 28.5 mg in 5 ml or 400 mg/57 mg in 5 ml is 2 times / day every 12 hours.

The recommended dosage regimen and frequency of use are presented below:

Frequency of use-3 times / day; suspension 4: 1 (125 mg / 31.25 mg in 5 ml):

• Low doses – 20 mg / kg / day.
• High doses – 40 mg / kg / day.

Dose rate-2 times / day; suspension 7: 1 (200 mg / 28.5 mg in 5 ml or 400 mg/57 mg in 5 ml):

• Low doses – 25 mg / kg / day.
• High doses – 45 mg / kg / day.

Low-dose Augmentin® is used to treat skin and soft tissue infections, as well as recurrent tonsillitis.

High doses of Augmentin® are used to treat diseases such as otitis media, sinusitis, lower respiratory and urinary tract infections, bone and joint infections.

There are insufficient clinical data to recommend the use of Augmentin® at a dose of more than 40 mg / kg / day in 3 doses (suspension 4:1) in children under 2 years of age.

Children from birth to 3 months

Due to immaturity of the excretory function of the kidneys, the recommended dose of Augmentin® (calculated according to amoxicillin) is 30 mg / kg / day in 2 doses in the form of a 4:1 suspension.

The use of a 7: 1 suspension (200 mg / 28.5 mg in 5 ml or 400 mg/57 mg in 5 ml) is not recommended in this population.

Children born prematurely

There are no recommendations regarding the dosage regimen.

Elderly patients

No dose adjustment is required. In elderly patients with impaired renal function, the dose should be adjusted as indicated below for adults with impaired renal function.

Patients with impaired renal function

Dose adjustment is based on the maximum recommended dose of amoxicillin and is carried out taking into account the values of creatinine clearance.

Adults

Tablets 250 mg+125 mg or 500 mg+125 mg:

• Creatinine clearance > 30 ml / min – no dosage adjustment is required.
• Creatinine clearance 10-30 ml / min – 1 tab. 250 mg+125 mg 2 times/day or 1 tab. 500 mg+125 mg (for mild and moderate infection) 2 times / day.
• QC 250 mg+125 mg 1 time/day or 1 tab. 500 mg+125 mg (for mild and moderate infection) 1 time/day.

4: 1 suspension (125 mg / 31.25 mg in 5 ml):

• Creatinine clearance > 30 ml / min – no dosage adjustment is required.
• Creatinine clearance 10-30 ml / min – 15 mg / 3.75 mg / kg 2 times / day, maximum dose-500 mg / 125 mg 2 times/day.
• Creatinine clearance < 10 ml / min – 15 mg / 3.75 mg / kg 1 time / day, the maximum daily dose is 500 mg/125 mg.

875 mg+125 mg tablets and 7:1 suspension (200 mg/28.5 mg in 5 ml or 400 mg/57 mg in 5 ml) should only be used in patients with creatinine clearance > 30 ml / min, and no dose adjustment is required.

In most cases, if possible, parenteral therapy should be preferred.

Patients undergoing hemodialysis

Dose adjustments are based on the maximum recommended dose of amoxicillin: 2 tablets. 250 mg / 125 mg in one dose every 24 hours, or 1 tab. 500 mg / 125 mg in one dose every 24 hours, or suspension at a dose of 15 mg/3.75 mg / kg 1 time / day.

Tablets: during the hemodialysis session, an additional 1 dose (one tablet) and another 1 dose (one tablet) at the end of the dialysis session (to compensate for the decrease in serum concentrations of amoxicillin and clavulanic acid).

Suspension: One additional dose of 15 mg/3.75 mg/kg should be administered before the hemodialysis session. To restore the concentration of the active components of Augmentin® in the blood, a second additional dose of 15 mg/3.75 mg/kg should be administered after a hemodialysis session.

Patients with impaired liver function

Treatment is carried out with caution; liver function is regularly monitored. There is insufficient data to correct the dosage regimen in this category of patients.

Suspension preparation rules

The suspension is prepared immediately before the first application.

Suspension (125 mg / 31.25 mg in 5 ml): add approximately 60 ml of boiled water cooled to room temperature to the powder bottle, then close the bottle with a lid and shake until the powder is completely diluted, let the bottle stand for 5 minutes to ensure complete dilution. Then add water up to the mark on the bottle and shake the bottle again. In general, about 92 ml of water is required to prepare the suspension. The bottle should be shaken well before each use. For accurate dosage of the drug, a measuring cap should be used, which should be thoroughly washed with water after each application. After dilution, the suspension should be stored for no more than 7 days in the refrigerator, but not frozen.

For children under 2 years of age, the measured single dose of Augmentin® suspension can be diluted twice with water.

Suspension (200 mg / 28.5 mg in 5 ml or 400 mg/57 mg in 5 ml): add approximately 40 ml of boiled water cooled to room temperature to the powder bottle, then close the bottle with a lid and shake until the powder is completely diluted, let the bottle stand for 5 minutes to ensure complete dilution. Then add water up to the mark on the bottle and shake the bottle again. In general, about 64 ml of water is required to prepare the suspension. The bottle should be shaken well before each use. For accurate dosage of the drug, you should use a measuring cap or a dosing syringe, which must be thoroughly washed with water after each application. After dilution, the suspension should be stored for no more than 7 days in the refrigerator, but not frozen.

For children under 2 years of age, the measured single dose of Augmentin® suspension can be diluted with water in a ratio of 1: 1.

Overdose

Symptoms: there may be symptoms from the gastrointestinal tract and violations of the water-electrolyte balance. Amoxicillin crystalluria is described, which in some cases leads to the development of renal failure.

Seizures may occur in patients with impaired renal function, as well as in those receiving high doses of the drug.

Treatment: symptoms from the gastrointestinal tract-symptomatic therapy, paying special attention to the normalization of water and electrolyte balance. In case of overdose, amoxicillin and clavulanic acid can be removed from the bloodstream by hemodialysis.

The results of a prospective study conducted with 51 children in a toxicology center showed that use of amoxicillin at a dose of less than 250 mg / kg did not lead to significant clinical symptoms and did not require gastric lavage.

Special instructions

Before starting treatment with Augmentin®, a detailed medical history should be collected regarding previous hypersensitivity reactions to penicillins, cephalosporins or other allergens.

Serious, and sometimes fatal, hypersensitivity reactions (anaphylactic reactions) to penicillins have been described. The risk of such reactions is highest in patients with a history of hypersensitivity reactions to penicillins. If an allergic reaction occurs, discontinue treatment with Augmentin® and start appropriate alternative therapy. In case of serious hypersensitivity reactions, epinephrine should be administered immediately. Oxygen therapy, intravenous corticosteroids, and airway patency, including intubation, may also be required.

It is not recommended to prescribe Augmentin® if infectious mononucleosis is suspected, since in patients with this disease, amoxicillin can cause a crust-like rash, which makes it difficult to diagnose the disease.

Long-term treatment with Augmentin® sometimes leads to an excessive proliferation of insensitive microorganisms.

In general, Augmentin® is well tolerated and has a low toxicity characteristic of all penicillins.

During long-term therapy with Augmentin®, it is recommended to periodically evaluate the function of the kidneys, liver and hematopoiesis.

In order to reduce the risk of side effects from the gastrointestinal tract, the drug should be taken at the beginning of a meal.

In patients receiving a combination of amoxicillin and clavulanic acid together with indirect (oral) anticoagulants, in rare cases, an increase in prothrombin time (increased MHO) has been reported. When co-prescribing indirect (oral) anticoagulants with a combination of amoxicillin and clavulanic acid, monitoring of appropriate indicators is necessary. Dose adjustments may be necessary to maintain the desired effect of oral anticoagulants.

In patients with impaired renal function, the dose of Augmentin® should be reduced accordingly to the degree of impairment.

Crystalluria has been reported in very rare cases in patients with reduced diuresis, mainly with parenteral use of the drug. During the use of high doses of amoxicillin, it is recommended to take sufficient fluids and maintain adequate diuresis to reduce the likelihood of amoxicillin crystals forming.

Oral use of Augmentin® leads to a high content of amoxicillin in the urine, which can lead to false positive results in the determination of glucose in the urine (for example, Benedict test, Fehling test). In this case, it is recommended to use a glucose-oxidant method for determining the concentration of glucose in the urine.

Oral care helps prevent discoloration of the teeth, as it is enough to brush your teeth.

Tablets must be used within 30 days of opening the laminated aluminum foil package.

Abuse and drug addiction

There were no drug dependence, addiction, or euphoric reactions associated with the use of Augmentin®.

Influence on the ability to drive motor vehicles and manage mechanisms

Since the drug can cause dizziness, it is necessary to warn patients about precautions when driving a vehicle or working with moving mechanisms.

Form of production

Film-coated tablets.

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

2 years

Active ingredient

Amoxicillin, Clavulanic Acid

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Purpose

Nursing mothers as prescribed by a doctor, Pregnant women as prescribed by a doctor, Children as prescribed by a doctor, Adults as prescribed by a doctor, Children over 12 years of age

Indications

Otitis Media, Urinary Tract Infections, Sinusitis, Skin Infections, Bronchitis, Osteomyelitis, Pneumonia, Periodontitis, Sore Throat